Kevin Pando @Kevin_Pando: "Boston Scientific beats Q2, but..."

Italy

Boston Scientific beats Q2, but lowers expectations for the rest of the year. Boston Scientific delivered a solid second quarter, reporting $5.44B in revenue (+7.5% YoY), ahead of the $5.36B consensus, while adjusted EPS came in at $0.86, beating expectations of $0.83. The positive quarter was driven by continued strength in its cardiovascular business, with operating margin improving to 21.6%. However, investors are looking beyond the headline numbers. Management guided Q3 revenue to $5.27B, below the $5.39B expected by Wall Street, and reduced its full-year adjusted EPS guidance to $3.28–$3.32 (from $3.34–$3.41 previously). The company also lowered its expected 2026 organic sales growth to 5–6%, versus the prior 6.5–8% outlook. The weaker outlook reflects softer demand for the Watchman heart device, as more physicians combine the procedure with other cardiac treatments, reducing standalone implant volumes. At the same time, Boston Scientific announced a multi-year restructuring plan focused on optimizing its supply chain, manufacturing footprint, and organizational structure to improve long-term efficiency. The takeaway? The business continues to execute well, but expectations for near-term growth have been reset. For long-term investors, the key question is whether today's guidance cut is simply a temporary headwind or the beginning of a more sustained slowdown. Do you think the market will focus more on the earnings beat or the weaker outlook? $SPX500 $NSDQ100 $DJ30 $BSX.US (Boston Scientific Corp) $OIL $NATGAS $GOLD

Not investment advice. The author may have financial interests in the mentioned instruments.